TAM
VRTX icon

Tocqueville Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Tocqueville Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-770
Closed -$224K – 676
2020
Q2 		$224K Sell
770
-1,500
-66% -$407K ﹤0.01% 613
2020
Q1 		$540K Buy
2,270
+725
+47% +$166K 0.01% 441
2019
Q4 		$338K Buy
+1,545
New +$313K 0.01% 626
2019
Q2 		– Sell
-15,110
Closed -$2.78M – 804
2019
Q1 		$2.78M Buy
15,110
+2,275
+18% +$420K 0.04% 348
2018
Q4 		$2.13M Sell
12,835
-28,180
-69% -$4.88M 0.03% 375
2018
Q3 		$7.91M Buy
41,015
+2,775
+7% +$494K 0.1% 221
2018
Q2 		$6.5M Sell
38,240
-3,165
-8% -$491K 0.08% 246
2018
Q1 		$6.75M Sell
41,405
-611
-1% -$99.8K 0.09% 239
2017
Q4 		$6.3M Buy
42,016
+40,640
+2,953% +$6.02M 0.07% 275
2017
Q3 		$209K Sell
1,376
-200
-13% -$30.1K ﹤0.01% 764
2017
Q2 		$203K Buy
+1,576
New +$190K ﹤0.01% 751
2016
Q4 		– Sell
-32,466
Closed -$2.83M – 856
2016
Q3 		$2.83M Sell
32,466
-24,565
-43% -$2.32M 0.03% 367
2016
Q2 		$4.91M Sell
57,031
-1,100
-2% -$95K 0.06% 294
2016
Q1 		$4.62M Sell
58,131
-6,675
-10% -$604K 0.06% 290
2015
Q4 		$8.15M Buy
64,806
+2,375
+4% +$287K 0.11% 211
2015
Q3 		$6.5M Buy
62,431
+7,070
+13% +$908K 0.09% 254
2015
Q2 		$6.84M Buy
55,361
+645
+1% +$81.3K 0.08% 259
2015
Q1 		$6.46M Buy
54,716
+100
+0.2% +$12K 0.08% 277
2014
Q4 		$6.49M Sell
54,616
-1,450
-3% -$163K 0.07% 280
2014
Q3 		$6.3M Buy
56,066
+500
+0.9% +$47.6K 0.07% 257
2014
Q2 		$5.26M Sell
55,566
-5,000
-8% -$351K 0.05% 306
2014
Q1 		$4.28M Sell
60,566
-200
-0.3% -$15.8K 0.06% 278
2013
Q4 		$4.51M Sell
60,766
-590
-1% -$41.1K 0.06% 269
2013
Q3 		$4.65M Sell
61,356
-2,050
-3% -$163K 0.06% 310
2013
Q2 		$5.08M Buy
+63,406
New +$4.67M 0.07% 277

Other funds holding VRTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Tocqueville Asset Management's VRTX Position: Q3 2020 in Review

Tocqueville Asset Management sold out of Vertex Pharmaceuticals (VRTX) in Q3 2020, closing a stake of 770 shares — an estimated $224K sold.

Tocqueville Asset Management first reported a position in VRTX in Q2 2013 and held it in 25 quarters. The position peaked at $8.15M in Q4 2015. 951 funds tracked by Wall St. Rank hold VRTX as of Q3 2020.

  • Tocqueville Asset Management reported no remaining Vertex Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Tocqueville Asset Management sold 770 Vertex Pharmaceuticals shares in Q3 2020, an estimated $224K.
  • Tocqueville Asset Management first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 25 quarters.
  • Tocqueville Asset Management's Vertex Pharmaceuticals position peaked at $8.15M in Q4 2015.
  • 951 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2020.

Based on Tocqueville Asset Management's 13F filing for Q3 2020, filed 16 Nov 2020.